TY - JOUR
T1 - The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients
AU - Na, Rong
AU - Wei, Jun
AU - Sample, Chris J.
AU - Gielzak, Marta
AU - Choi, Sodam
AU - Cooney, Kathleen A.
AU - Rabizadeh, Daniel
AU - Walsh, Patrick C.
AU - Zheng, Lilly S.
AU - Xu, Jianfeng
AU - Isaacs, William B.
N1 - Funding Information:
The generous support from the Patrick C Walsh Hereditary Prostate Cancer program is gratefully acknowledged.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/3/23
Y1 - 2022/3/23
N2 - Background: Recently, a novel HOXB13 variant (X285K) was observed in men of African descent with prostate cancer (PCa) in Martinique. Little is known about this or other variants in HOXB13 which may play a role in PCa susceptibility in African-American (AA) men. Methods: We sequenced HOXB13 in an AA population of 1048 men undergoing surgical treatment for PCa at Johns Hopkins Hospital. Results: Seven non-synonymous germline variants were observed in the patient population. While six of these variants were seen only once, X285K was found in eight patients. In a case–case analysis, we find that carriers of this latter variant are at increased risk of clinically significant PCa (1.2% carrier rate in Gleason Score ≥7 PCa vs. 0% in Gleason Score <7 PCa, odds ratio, OR = inf; 95% Confidence Interval, 95%CI:1.05-inf, P = 0.028), as well as PCa with early age at diagnosis (2.4% carrier rate in patients <50 year vs. 0.5% carrier rate in patients ≥50 year, OR = 5.25, 95% CI:1.00–28.52, P = 0.03). Conclusions: While this variant is rare in the AA population (~0.2% MAF), its ancestry-specific occurrence and apparent preferential association with risk for the more aggressive disease at an early age emphasizes its translational potential as an important, novel PCa susceptibility marker in the high-risk AA population.
AB - Background: Recently, a novel HOXB13 variant (X285K) was observed in men of African descent with prostate cancer (PCa) in Martinique. Little is known about this or other variants in HOXB13 which may play a role in PCa susceptibility in African-American (AA) men. Methods: We sequenced HOXB13 in an AA population of 1048 men undergoing surgical treatment for PCa at Johns Hopkins Hospital. Results: Seven non-synonymous germline variants were observed in the patient population. While six of these variants were seen only once, X285K was found in eight patients. In a case–case analysis, we find that carriers of this latter variant are at increased risk of clinically significant PCa (1.2% carrier rate in Gleason Score ≥7 PCa vs. 0% in Gleason Score <7 PCa, odds ratio, OR = inf; 95% Confidence Interval, 95%CI:1.05-inf, P = 0.028), as well as PCa with early age at diagnosis (2.4% carrier rate in patients <50 year vs. 0.5% carrier rate in patients ≥50 year, OR = 5.25, 95% CI:1.00–28.52, P = 0.03). Conclusions: While this variant is rare in the AA population (~0.2% MAF), its ancestry-specific occurrence and apparent preferential association with risk for the more aggressive disease at an early age emphasizes its translational potential as an important, novel PCa susceptibility marker in the high-risk AA population.
UR - http://www.scopus.com/inward/record.url?scp=85119530021&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119530021&partnerID=8YFLogxK
U2 - 10.1038/s41416-021-01622-4
DO - 10.1038/s41416-021-01622-4
M3 - Article
C2 - 34799695
AN - SCOPUS:85119530021
SN - 0007-0920
VL - 126
SP - 791
EP - 796
JO - British journal of cancer
JF - British journal of cancer
IS - 5
ER -